NEW YORK, Sept. 17 (GenomeWeb News) - 454 has extended a one-year license to now include exclusive rights to synthesizing technologies owned by Biotage, the company said today.

New Haven, Conn.-based 454 has obtains the rights to sequencing by synthesis and pyrophosphate-based sequencing for whole genome and other high density and high-throughput applications.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Popular Mechanics reports that Caltech researchers have built a prototype nanobot using DNA.

The Sacramento Bee writes that direct-to-consumer genetic testing connected a woman to sperm donor-conceived half siblings.

In PLOS this week: gene expression catalog for sheep, viral diversity among respiratory samples from camels, and more.